In fact, GNP-LLO91–99 nanovaccines adequately combine well and potentiate the action of ICI—both anti-CTLA-4 and anti-PD-1—supporting them as a novel nano-immunotherapy for BC. Here, CTLA4 is linked to breast cancer.